2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2487

Effects of Tofacitinib on Health Care Resource Utilization and Work Productivity in US Patients with Rheumatoid Arthritis
Abstract Number: 507

Efficacy and Safety of Adalimumab Therapy in Japanese Patients with Rheumatoid Arthritis
Abstract Number: 2757

Efficacy and Safety of ANTI-TNF ALPHA in BEHÇET Disease: A International Multicenter Registry of 122 Patients
Abstract Number: 1483

Efficacy and Safety of Baricitinib in Japanese Rheumatoid Arthritis Patients during a 52 Week Extension Phase
Abstract Number: 175

Efficacy and Safety of Canakinumab in Acute Gouty Arthritis Patients with Chronic Kidney Disease Stage Greater Than or Equal to 3: A Post-Hoc Analysis of 12-Week Data
Abstract Number: 264

Efficacy and Safety of Cannabinoid Treatments in the Rheumatic Diseases: A Systematic Review of Randomized Controlled Trials
Abstract Number: 481

Efficacy and Safety of Etanercept in Rheumatoid Arthritis Patients over 75 Years Old
Abstract Number: 2269

Efficacy and Safety of High Dose Infliximab in the Treatment of Uveitis in Pediatric Patients
Abstract Number: 1793

Efficacy and Safety of IFN-Alpha in Induction and Maintenance of Remission in Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA). Single Center Observational Study
Abstract Number: 1497

Efficacy and Safety of Iguratimod for Rheumatoid Arthritis
Abstract Number: 496

Efficacy and Safety of Induction Therapy for Rheumatoid Arthritis with Simultaneous Administration of Methotrexate and Low-Dose Tacrolimus: A Retrospective Study
Abstract Number: 1528

Efficacy and Safety of MK-8457, a Novel SYK Inhibitor for the Treatment of Rheumatoid Arthritis in Two Randomized, Controlled, Phase 2 Studies
Abstract Number: 947

Efficacy and Safety of NNC01140006, an Anti-IL-21 Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis
Abstract Number: 2855

Efficacy and Safety of Rituximab Retreatment Regimen at Clinical Relapse in Severe Cryoglobulinemic Vasculitis
Abstract Number: L25

Efficacy and Safety of Subcutaneous Tabalumab in Patients with Systemic Lupus Erythematosus (SLE): Results from 2 Phase 3, 52-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trials

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].